![]()
|
|
||||||||
J. Biol. Chem., Vol. 278, Issue 34, 32335-32343, August 22, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



**
From the
Department of Biochemistry, Faculty of
Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Kumamoto,
862-0973, the ¶Tsukuba Primate Center for Medical
Science, National Institute of Infectious Diseases, Tsukuba, Ibaraki 305-0843,
and the ||Research Laboratory, Nissui
Pharmaceutical Co., Ltd., Ibaraki 307-0036, Japan
A novel synthetic peptide immunogen targeting the human immunodeficiency
virus type-1 (HIV-1) coreceptor CXCR4 was evaluated for its capacity to induce
CXCR4-specific antibodies with anti-HIV-1 activity in BALB/c mice and
cynomolgus monkeys. A cyclic closed-chain dodecapeptide mimicking the
conformation-specific domain of CXCR4 (cDDX4) was prepared in which Gly-Asp,
as the dipeptide forming a spacer arm, links the amino and carboxyl termini of
the decapeptidyl linear chain (linear DDX4, Asn176 to
Ile185) derived from the undecapeptidyl arch (UPA;
Asn176 to Cys186) of extracellular loop 2 (ECL-2) in
CXCR4. Immunization of BALB/c mice with cDDX4 conjugated with a
multiple-antigen peptide (cDDX4-MAP) induced conformational epitope-specific
antibodies, and monoclonal antibody IA2-F9 reacted with cDDX4, but not with
linear DDX4, as determined by real-time biomolecular interaction analysis
using surface plasmon resonance. The antibody also reacted with cells
expressing CXCR4 but not with cells expressing the other HIV coreceptor, CCR5.
Furthermore, the antibody inhibited the replication of HIV-1 X4 virus (using
CXCR4), as shown by an infection assay using both MAGIC-5 cells and MT4 cells,
but not that of HIV-1 R5 virus (using CCR5). The antibody weakly interfered
with chemotaxis induced by stromal cell-derived factor-1
in THP-1 cells
or moderately inhibited the chemotaxis of Molt4#8 cells under the same
conditions. In addition, immunization of cynomolgus monkeys also induced
cDDX4-specific antibodies with anti-HIV activity. Taken together, these
results indicate that cDDX4 conjugated with a multi-antigen peptide induces
the conformational epitope-specific antibodies to the undecapeptidyl arch of
CXCR4 may be a novel candidate immunogen for preventing disease progression in
HIV-1-infected individuals.
Received for publication, February 4, 2003 , and in revised form, April 30, 2003.
* This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan, and Japan Health Science Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Both authors contributed equally to this work.
** To whom correspondence should be addressed. Tel.: 81-96-371-4362; Fax: 81-96-362-7800; E-mail address: shoji{at}gpo.kumamoto-u.ac.jp.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D. Nakayama, S. Misumi, R. Mukai, K. Tachibana, M. Umeda, H. Shibata, N. Takamune, and S. Shoji Suppression of Multiclade R5 and X4 Human Immunodeficiency Virus Type-1 Infections by a Coreceptor-Based Anti-HIV Strategy J. Biochem., November 1, 2005; 138(5): 571 - 582. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |